A practical reference on elevated plus maze: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Among Sporck's cost control efforts was his offshore outsourcing of labour. National Semiconductor was among the pioneers in the semiconductor industry to invest in facilities to perform final manufacturing operations of integrated circuits in developing countries, especially in Southeast Asia. National Semiconductor's manufacturing improvements under Sporck (in collaboration with Lamond) was enabled not by emphasizing process innovation but by improving and standardizing processes already established by other companies like Fairchild and Texas Instruments, as well as by frequent raiding to hire from Fairchild's pool of talents.
The oldest definitive evidence for fire making (i.e. igniting a new fire) dates to ~400,000 years ago at a Neanderthal site in Suffolk, England, where burnt soil was found along with fire-cracked flint handaxes and two fragments of iron pyrite, used to strike sparks with flint. At other sites in France dating from 50,000 years ago onwards, dozens of Neanderthal hand axes exhibit use-wear traces suggesting they were struck with pyrite to produce sparks. Ötzi, a well-preserved natural mummy of a man who lived in the Ötztal Alps between 3350 and 3105 BCE, carried fire-making material in the form of tinder fungus with flint and pyrite for creating sparks. The Kaurna people of South Australia have used pyrite with flintstone and a form of tinder made of stringybark as a traditional method of starting fires. Pyrite has been used since classical times to manufacture copperas (ferrous sulfate). Iron pyrite was heaped up and allowed to weather (an example of an early form of heap leaching). The acidic runoff from the heap was then boiled with iron to produce iron sulfate. In the 15th century, new methods of such leaching began to replace the burning of sulfur as a source of sulfuric acid. By the 19th century it had become the dominant method. Marcasite jewelry, using small faceted pieces of pyrite, often set in silver, has been made since ancient times and was popular in the Victorian era.
Clostripain (EC 3.4.22.8, clostridiopeptidase B, clostridium histolyticum proteinase B, alpha-clostridipain, clostridiopeptidase, Endoproteinase Arg-C) is a cysteine protease that cleaves proteins on the carboxyl peptide bond of arginine. It was isolated from Clostridium histolyticum. The isoelectric point of the enzyme is 4.8-4.9 (at 8 °C), and optimum pH is 7.4~7.8 (against α-benzoyl-arginine ethyl ester). The composition of the enzyme is indicated to be of two chains of relative molecular mass 45,000 and 12,500.
=== 1963–1998: Bob Rosenberg === In 1963, Rosenberg's son Bob became CEO of the company at age 25, and Dunkin' Donuts opened its hundredth location that year. Dunkin' Donuts was a subsidiary of Universal Food Systems at the time, a conglomerate of 10 small food-service businesses, and Dunkin' Donuts locations varied greatly in their menu options, with some selling full breakfasts and others serving only doughnuts and coffee. In the following years, the other businesses in the Universal Food Systems portfolio were sold or closed, and the company was renamed to Dunkin' Donuts. The menu and shop format was standardized, and various new menu items were introduced. In the early 1980s, counter service and ceramic coffee cups were replaced by self-service counters and paper cups. The chain went public in 1968 and was acquired by Baskin-Robbins owner Allied Lyons in 1990. Dunkin' Donuts expanded in the 1990s by buying out two rival chains: Mister Donut (which was founded by Bill Rosenberg's former partner Harry Winokur) and Dawn Donuts.
Sources: en.wikipedia.org
== Career == She completed her secondary education at the Reformed College of Debrecen, graduating in 1971. She earned her medical degree summa cum laude from the University of Debrecen Medical School in 1977. Between 1977 and 1982, she worked at the Department of Anatomy, Histology and Embryology of the University of Debrecen Medical School. Then, from 1982 to 1993, she was a staff member of the Department of Clinical Chemistry. She held research fellowships at the State University of New York (1988), Thomas Jefferson University in Philadelphia (1989–1990), and Gifu University in Japan (1992). She obtained the Doctor of the Hungarian Academy of Sciences (D.Sc.) degree in 1992. In 1993, she was appointed full professor and director of the Department of Public Health and Epidemiology (later the Department of Preventive Medicine), a position she held until 2017. From 2005 to 2012 she served as the founding dean of the Faculty of Public Health at the University of Debrecen, and between 2007 and 2013 she was the vice-president responsible for medical specialization and postgraduate training of the Medical and Health Science Centre. From 2021 to 2024, she was a visiting professor at Semmelweis University and senior adviser to the Epidemiology and Surveillance Centre. Since November 2024, she has been a professor at the Institute of Preventive Medicine and Public Health of Semmelweis University.
== Applications == The triple quadrupole mass spectrometer allows for increased sensitivity and specificity yielding lower detection and quantitation limits. For these reasons, employment of the TQMS is a vital asset in the fields of drug metabolism, pharmacokinetics, environmental studies, and biological analyses. In most drug and pharmacokinetic studies, animals like rats, are subjected to a new drug in order to probe how the substance metabolizes in the body. By analyzing the rat’s urine or plasma with a triple quadrupole coupled to liquid chromatography, the concentration and fragmentation pattern of the new drug can be determined. In environmental and biological studies, the triple quadrupole is useful for quantitative studies that involved identifying whether or not specific substances are present in a sample. One of the more common uses of a triple quadrupole mass analyzer is for structural elucidation, which provides information about fragmentation patterns. However, a mass spectrum only provides information about fragmentation, which isn't enough information to fully deduce the structure of a molecule or compound. So for the purpose of structural elucidation, it is paired with data obtained from other analytical methods, like nuclear magnetic resonance (NMR) spectroscopy and infrared spectroscopy (IR), for a more accurate analysis.
Girteka is a Lithuanian transport and logistics company based in the city of Vilnius, operating in Europe and Scandinavia. It was founded in 1996 by Mindaugas Raila who, at the age of 24, bought a single used truck complete with a trailer. Today, it is one of Europe's largest asset-based logistics companies. Girteka delivers more than 700,000 full truck loads (FTLs) every year, with more than 6,000 fully owned trucks and 7,000 trailers that operate across mainland Europe, the UK, and Scandinavia. Up to 95% of jobs are dispatched electronically, resulting in 97–99% DIFOT. Today, the company employs more than 13,000 people from more than 20 nationalities. Girteka has offices in Lithuania, Poland, Georgia, Denmark, Norway, Finland, Spain, Netherlands, Belgium, Ukraine, Belarus, Kazakhstan and Kyrgyzstan.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.